427 related articles for article (PubMed ID: 24050961)
1. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
Clavaguera F; Grueninger F; Tolnay M
Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
[TBL] [Abstract][Full Text] [Related]
2. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
3. Frontotemporal dementia with tau pathology.
Gasparini L; Terni B; Spillantini MG
Neurodegener Dis; 2007; 4(2-3):236-53. PubMed ID: 17596718
[TBL] [Abstract][Full Text] [Related]
4. Hyperexcitability and epileptic seizures in a model of frontotemporal dementia.
García-Cabrero AM; Guerrero-López R; Giráldez BG; Llorens-Martín M; Avila J; Serratosa JM; Sánchez MP
Neurobiol Dis; 2013 Oct; 58():200-8. PubMed ID: 23774255
[TBL] [Abstract][Full Text] [Related]
5. Neurodegenerative tauopathies.
Lee VM; Goedert M; Trojanowski JQ
Annu Rev Neurosci; 2001; 24():1121-59. PubMed ID: 11520930
[TBL] [Abstract][Full Text] [Related]
6. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
7. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
Zilka N; Korenova M; Novak M
Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
[TBL] [Abstract][Full Text] [Related]
8. Brief update on different roles of tau in neurodegeneration.
Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
[TBL] [Abstract][Full Text] [Related]
9. [Animal models of tauopathies].
Higuchi M
Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223
[TBL] [Abstract][Full Text] [Related]
10. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
11. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
Sorrentino G; Bonavita V
Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
[TBL] [Abstract][Full Text] [Related]
13. The neuropathological spectrum of neurodegenerative tauopathies.
Tolnay M; Probst A
IUBMB Life; 2003 Jun; 55(6):299-305. PubMed ID: 12938731
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
15. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
16. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
18. New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.
Medina M; Avila J
Biochem Pharmacol; 2014 Apr; 88(4):540-7. PubMed ID: 24462919
[TBL] [Abstract][Full Text] [Related]
19. Invited review: Prion-like transmission and spreading of tau pathology.
Clavaguera F; Hench J; Goedert M; Tolnay M
Neuropathol Appl Neurobiol; 2015 Feb; 41(1):47-58. PubMed ID: 25399729
[TBL] [Abstract][Full Text] [Related]
20. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
